Peter F. Favreau
YOU?
Author Swipe
View article: Supplementary Figure 1 from BCL-2 Family Inhibition Enhances mTORC1/2 Inhibition in <i>PIK3CA</i>-Mutant Colorectal Cancer
Supplementary Figure 1 from BCL-2 Family Inhibition Enhances mTORC1/2 Inhibition in <i>PIK3CA</i>-Mutant Colorectal Cancer Open
Supplementary Figure 1. High-throughput drug screen displays reproducibility across drugs within the same drug class and known negative controls.
View article: Supplementary Figure 2 from BCL-2 Family Inhibition Enhances mTORC1/2 Inhibition in <i>PIK3CA</i>-Mutant Colorectal Cancer
Supplementary Figure 2 from BCL-2 Family Inhibition Enhances mTORC1/2 Inhibition in <i>PIK3CA</i>-Mutant Colorectal Cancer Open
Supplementary Figure 2. Navitoclax enhances the responses of copanlisib in murine and human CRC lines.
View article: Supplementary Figure 3 from BCL-2 Family Inhibition Enhances mTORC1/2 Inhibition in <i>PIK3CA</i>-Mutant Colorectal Cancer
Supplementary Figure 3 from BCL-2 Family Inhibition Enhances mTORC1/2 Inhibition in <i>PIK3CA</i>-Mutant Colorectal Cancer Open
Supplementary Figure 3. Combination of copanlisib and navitoclax enhances apoptosis in multiple models of CRC.
View article: Subclonal response heterogeneity to define cancer organoid therapeutic sensitivity
Subclonal response heterogeneity to define cancer organoid therapeutic sensitivity Open
Tumor heterogeneity is predicted to confer inferior clinical outcomes with precision-based strategies, however, modeling heterogeneity in a manner that still represents the tumor of origin remains a formidable challenge. Sequencing technol…
View article: Human induced pluripotent stem cell-derived planar neural organoids assembled on synthetic hydrogels
Human induced pluripotent stem cell-derived planar neural organoids assembled on synthetic hydrogels Open
The tailorable properties of synthetic polyethylene glycol (PEG) hydrogels make them an attractive substrate for human organoid assembly. Here, we formed human neural organoids from iPSC-derived progenitor cells in two distinct formats: (i…
View article: Preclinical Models of Anal Cancer Combined-Modality Therapy
Preclinical Models of Anal Cancer Combined-Modality Therapy Open
View article: BIOL-19. DIFFUSE MIDLINE GLIOMA CEREBRAL ORGANOID MODEL AND MULTIOMICS CHARACTERIZATION
BIOL-19. DIFFUSE MIDLINE GLIOMA CEREBRAL ORGANOID MODEL AND MULTIOMICS CHARACTERIZATION Open
Diffuse midline glioma (DMG) are highly aggressive malignancies of the central nervous system that primarily affect the pediatric population. These tumors are historically universally fatal with no curative treatment options available. The…
View article: Data from MTORC1/2 Inhibition as a Therapeutic Strategy for <i>PIK3CA</i> Mutant Cancers
Data from MTORC1/2 Inhibition as a Therapeutic Strategy for <i>PIK3CA</i> Mutant Cancers Open
PIK3CA mutations are common in clinical molecular profiling, yet an effective means to target these cancers has yet to be developed. MTORC1 inhibitors are often used off-label for patients with PIK3CA mutant cancers with only…
View article: Supplementary Figure S1 from MTORC1/2 Inhibition as a Therapeutic Strategy for <i>PIK3CA</i> Mutant Cancers
Supplementary Figure S1 from MTORC1/2 Inhibition as a Therapeutic Strategy for <i>PIK3CA</i> Mutant Cancers Open
Supplementary Figure S1 presents the viability of SW48 and SW48PK cells after treatment with BEZ235 and TAK-228 at the 100-400nM concentrations.
View article: Supplementary Table S1 from MTORC1/2 Inhibition as a Therapeutic Strategy for <i>PIK3CA</i> Mutant Cancers
Supplementary Table S1 from MTORC1/2 Inhibition as a Therapeutic Strategy for <i>PIK3CA</i> Mutant Cancers Open
Supplementary Table S1 compares the intestinal tumor counts and percent of tumors progressing to cancer for mouse models with activating alterations in PIK3CA.
View article: Data from MTORC1/2 Inhibition as a Therapeutic Strategy for <i>PIK3CA</i> Mutant Cancers
Data from MTORC1/2 Inhibition as a Therapeutic Strategy for <i>PIK3CA</i> Mutant Cancers Open
PIK3CA mutations are common in clinical molecular profiling, yet an effective means to target these cancers has yet to be developed. MTORC1 inhibitors are often used off-label for patients with PIK3CA mutant cancers with only…
View article: Supplementary Table S1 from MTORC1/2 Inhibition as a Therapeutic Strategy for <i>PIK3CA</i> Mutant Cancers
Supplementary Table S1 from MTORC1/2 Inhibition as a Therapeutic Strategy for <i>PIK3CA</i> Mutant Cancers Open
Supplementary Table S1 compares the intestinal tumor counts and percent of tumors progressing to cancer for mouse models with activating alterations in PIK3CA.
View article: Supplementary Figure S1 from MTORC1/2 Inhibition as a Therapeutic Strategy for <i>PIK3CA</i> Mutant Cancers
Supplementary Figure S1 from MTORC1/2 Inhibition as a Therapeutic Strategy for <i>PIK3CA</i> Mutant Cancers Open
Supplementary Figure S1 presents the viability of SW48 and SW48PK cells after treatment with BEZ235 and TAK-228 at the 100-400nM concentrations.
View article: Table S2 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Table S2 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
Stock culture and feeding media.
View article: Figure S1 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Figure S1 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
Dot plots corresponding to population distribution curves and graphs of individual replicates for bar graphs in Figure 4.
View article: Figure S2 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Figure S2 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
Individual replicates for data shown in Figure 5B.
View article: Table S2 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Table S2 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
Stock culture and feeding media.
View article: Data from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Data from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
Purpose:Cancer treatment is limited by inaccurate predictors of patient-specific therapeutic response. Therefore, some patients are exposed to unnecessary side effects and delays in starting effective therapy. A clinical tool that predicts…
View article: Table S3 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Table S3 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
Detailed characteristics of CRC PDOCS.
View article: Supplementary Data from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Supplementary Data from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
Supplementary Methods
View article: Figure S2 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Figure S2 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
Individual replicates for data shown in Figure 5B.
View article: Figure S3 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Figure S3 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
Individual replicates for data shown in Figure 5E.
View article: Table S3 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Table S3 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
Detailed characteristics of CRC PDOCS.
View article: Supplementary Data from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Supplementary Data from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
Supplementary Methods
View article: Figure S4 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Figure S4 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
(A) Individual replicates of data shown in Figure 6A. (B) Individual replicates of data from Figure 6D.
View article: Figure S3 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Figure S3 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
Individual replicates for data shown in Figure 5E.
View article: Figure S1 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Figure S1 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
Dot plots corresponding to population distribution curves and graphs of individual replicates for bar graphs in Figure 4.
View article: Table S1 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Table S1 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
Success rates for growing human cancers in spheroid culture
View article: Table S1 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Table S1 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
Success rates for growing human cancers in spheroid culture
View article: Data from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Data from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
Purpose:Cancer treatment is limited by inaccurate predictors of patient-specific therapeutic response. Therefore, some patients are exposed to unnecessary side effects and delays in starting effective therapy. A clinical tool that predicts…